| Psoriasis vulgaris
Ilumya vs Sotyktu
Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.Deep comparison between: Ilumya vs Sotyktu with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSotyktu has a higher rate of injection site reactions vs Ilumya based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sotyktu but not Ilumya, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ilumya
Sotyktu
At A Glance
SC injection
Every 12 weeks
IL-23 antagonist
Oral
Daily
TYK2 inhibitor
Indications
- Psoriasis vulgaris
- Psoriasis vulgaris
- Arthritis, Psoriatic
Dosing
Psoriasis vulgaris 100 mg SC at Weeks 0, 4, and every 12 weeks thereafter.
Psoriasis vulgaris, Arthritis, Psoriatic 6 mg orally once daily, with or without food; do not crush, cut, or chew tablets; not recommended in severe hepatic impairment (Child-Pugh C).
Contraindications
- Previous serious hypersensitivity reaction to tildrakizumab-asmn or any excipient
- History of hypersensitivity reaction to deucravacitinib or any excipient in SOTYKTU
Adverse Reactions
Most common (>=1%) Upper respiratory infections, injection site reactions, diarrhea
Serious Hypersensitivity reactions, infections
Most common (>=1%) Upper respiratory infections, blood creatine phosphokinase increased, herpes simplex, mouth ulcers, folliculitis, acne
Serious Pneumonia, COVID-19, malignancies including breast cancer, hepatocellular carcinoma, and lymphoma
Pharmacology
Tildrakizumab is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor, thereby suppressing the release of proinflammatory cytokines and chemokines.
TYK2 inhibitor; deucravacitinib binds the regulatory domain of TYK2, allosterically inhibiting receptor-mediated TYK2 activation and downstream STAT signaling via the JAK-STAT pathway.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ilumya
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Sotyktu
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Ilumya
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Sotyktu
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Humana
Ilumya
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Sotyktu
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Psoriasis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Cost estimate not availableAssistance Fund: Psoriasis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
IlumyaView full Ilumya profile
SotyktuView full Sotyktu profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.